MarketPeel
Insider Trading Intelligence
Pricing
…
CL

Cormorant Asset Management, Lp

MLTX
10% OWNER · MOONLAKE IMMUNOTHERAPEUTICS · CIK 0001583977
FILING MIX · LIFETIME74%/26%
BUYS
113
SELLS
40
TOTAL VALUE
$375.98M
COMPANIES
19
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
34,793,277
AVG SELL PX
$6.63
TRADE KIND
SHOWING 153 / 153
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
107 backtested trades · 8 horizons · 40 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Cormorant Asset Management, Lp, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d107+62.62%+4.41%+0.80%+3.61%+3.97%2.03
14d107+53.27%+0.60%+1.48%-0.88%-2.24%-0.36
30d107+48.60%+1.04%+2.03%-0.96%-7.10%-0.44
60d107+64.49%+11.58%+4.78%+6.80%+2.31%1.75
90d107(1 pending)+62.26%+5.29%+5.73%-0.43%-1.09%-0.11
180d107(1 pending)+44.34%+1.66%+8.57%-6.72%-13.41%-1.09
1y107(8 pending)+25.25%-36.04%+19.73%-55.77%-77.92%-10.29
2y107(30 pending)+3.90%-25.65%+38.81%-64.46%-73.57%-8.43
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
MLTX · 1,994,173 shares · as of Sep 30, 2025
02,123,5384,247,0766,370,6138,494,15120242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 113 buys / 40 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DRUG
BRIGHT MINDS BIOSCIENCES INC.
SALE
109,331$89.50$9.79M950,000Apr 28, 2026Apr 30, 2026 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
SALE
30,029$11.46$344.0K2,344,971Dec 11, 2025Dec 15, 2025 ↗View →
EYPT
EYEPOINT, INC.
SALE
60,000$15.70$942.2K8,265,000Dec 4, 2025Dec 8, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
5,827$6.96$40.6K1,994,173Sep 30, 2025Oct 1, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
2,800,000$6.61$18.51M2,000,000Sep 29, 2025Oct 1, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
3,390,943$7.58$25.70M4,800,000Sep 29, 2025Oct 1, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
70,748$9.38$663.6K8,423,403Sep 29, 2025Oct 1, 2025 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
SALE
232,460$8.40$1.95M8,190,943Sep 29, 2025Oct 1, 2025 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASEGRANT
Stock grant
91,970——91,970Jun 11, 2025Jun 13, 2025 ↗View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
1,813,439$1.85$3.36M0May 15, 2025May 19, 2025 ↗View →
OKUR
ONKURE THERAPEUTICS, INC.
SALE
24,300$1.99$48.2K1,813,439May 12, 2025May 14, 2025 ↗View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
800,189——800,189Feb 14, 2025Feb 19, 2025 ↗View →
AARD
AARDVARK THERAPEUTICS, INC.
PURCHASE
187,500$16.00$3.00M987,689Feb 14, 2025Feb 19, 2025 ↗View →
AARD
AARDVARK THERAPEUTICS, INC.
SALE
6,780,810——0Feb 14, 2025Feb 19, 2025 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
184,331$21.70$4.00M1,059,331Nov 4, 2024Nov 6, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
3,107$25.22$78.4K875,000Oct 16, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
7,150$24.03$171.8K871,893Oct 16, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
39,743$23.22$922.6K864,743Oct 16, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
33,343$6.42$214.2K787,022Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
238,097$4.53$1.08M690,506Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
2,700$9.26$25.0K801,222Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
63,173$5.92$374.2K753,679Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
19,169$11.72$224.6K820,391Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
8,900$7.31$65.0K795,922Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
2,600$8.80$22.9K798,522Oct 15, 2024Oct 17, 2024 ↗View →
DRUG
BRIGHT MINDS BIOSCIENCES INC.
PURCHASE
4,609$12.35$56.9K825,000Oct 15, 2024Oct 17, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
450,000$18.00$8.10M1,629,529Sep 27, 2024Oct 1, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
PURCHASE
1,179,529——1,179,529Sep 27, 2024Oct 1, 2024 ↗View →
BIOA
BIOAGE LABS, INC.
SALE
5,263,772——0Sep 27, 2024Oct 1, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
45,085$17.48$787.9K2,070,085Sep 20, 2024Sep 24, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
139,551$20.42$2.85M2,301,667Sep 20, 2024Sep 24, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
25,769$22.23$572.8K2,375,000Sep 20, 2024Sep 24, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
66,088$19.61$1.30M2,162,116Sep 20, 2024Sep 24, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
25,943$18.36$476.3K2,096,028Sep 20, 2024Sep 24, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
47,564$21.47$1.02M2,349,231Sep 20, 2024Sep 24, 2024 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASEGRANT
Stock grant
51,025——51.025Jun 12, 2024Jun 13, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
207,153$12.36$2.56M8,325,000May 6, 2024May 8, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
642,847$11.70$7.52M8,117,847May 6, 2024May 8, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
186,521$18.90$3.53M7,475,000Apr 18, 2024Apr 22, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
395,244$17.62$6.96M7,288,479Apr 18, 2024Apr 22, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
300$3.07$9203,294,873Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
600$3.03$1.8K3,294,173Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
280$2.97$8323,293,873Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
10$2.98$303,294,153Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
100$3.05$3053,294,773Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
10$3.01$303,294,163Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
398,600$2.90$1.16M2,895,273Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
100$3.07$3073,295,173Apr 1, 2024Apr 3, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
400,000$2.14$856.4K3,295,273Mar 15, 2024Mar 18, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
54,215$5.37$291.4K3,706,313Mar 14, 2024Mar 18, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
345,266$3.24$1.12M3,859,098Mar 14, 2024Mar 18, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
98,570$4.25$418.4K3,760,528Mar 14, 2024Mar 18, 2024 ↗View →
IMRX
IMMUNEERING CORP
SALE
11,040$5.97$65.9K3,695,273Mar 14, 2024Mar 18, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
24,983$42.25$1.06M1,779,325Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
8,862$45.96$407.3K2,025,000Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
18,548$43.26$802.4K1,797,873Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
156,597$45.26$7.09M2,016,138Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
61,668$44.62$2.75M1,859,541Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
29,342$41.23$1.21M1,754,342Mar 8, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
46,799$37.82$1.77M1,521,799Mar 7, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
102,140$41.23$4.21M1,725,000Mar 7, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
10,736$39.13$420.1K1,532,535Mar 7, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
90,325$39.99$3.61M1,622,860Mar 7, 2024Mar 11, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
750,000$19.00$14.25M1,475,000Feb 2, 2024Feb 6, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
2,654$31.00$82.3K571,672Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
3,866$32.47$125.5K579,663Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
31,549$34.62$1.09M629,267Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
16,484$36.53$602.2K678,046Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
43,754$37.49$1.64M721,800Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
15,243$26.66$406.4K471,999Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
31,028$28.82$894.2K539,774Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
14,388$25.73$370.2K456,756Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
29,244$29.42$860.4K569,018Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
36,747$27.70$1.02M508,746Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
18,055$33.71$608.6K597,718Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
3,200$38.49$123.2K725,000Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
32,295$35.83$1.16M661,562Jan 26, 2024Jan 30, 2024 ↗View →
CRBP
CORBUS PHARMACEUTICALS HOLDINGS, INC.
PURCHASE
4,125$31.86$131.4K575,797Jan 26, 2024Jan 30, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
750,000$19.75$14.81M6,893,235Jan 11, 2024Jan 11, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
105,000$21.32$2.24M6,143,235Jan 9, 2024Jan 11, 2024 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
588,235$17.00$10.00M6,038,235Dec 8, 2023Dec 12, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
19,866$33.75$670.5K5,441,740Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
28,090$22.80$640.5K5,028,386Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
18,601$29.91$556.4K5,277,755Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
8,168$28.78$235.1K5,259,154Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
37,081$24.01$890.3K5,065,467Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
321,259$18.80$6.04M3,852,202Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
15,582$30.74$479.0K5,293,337Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
65,086$25.88$1.68M5,170,452Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
86,713$31.83$2.76M5,380,050Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
41,824$33.08$1.38M5,421,874Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
122,625$20.62$2.53M4,920,491Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
945,664$19.88$18.80M4,797,866Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
79,805$21.87$1.75M5,000,296Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
39,899$24.87$992.3K5,105,366Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
8,260$34.49$284.9K5,450,000Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
53,109$26.73$1.42M5,223,561Dec 4, 2023Dec 6, 2023 ↗View →
EYPT
EYEPOINT, INC.
PURCHASE
27,425$27.87$764.3K5,250,986Dec 4, 2023Dec 6, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
58,839$59.90$3.52M8,494,151Oct 5, 2023Oct 10, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
67,814$57.32$3.89M8,435,312Oct 4, 2023Oct 4, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
150,487$57.25$8.62M8,367,498Oct 3, 2023Oct 4, 2023 ↗View →
MLTX
MOONLAKE IMMUNOTHERAPEUTICS
PURCHASE
74,911$57.37$4.30M8,217,011Oct 2, 2023Oct 4, 2023 ↗View →
ERAS
ERASCA, INC.
PURCHASEGRANT
Stock grant
60,000——60,000Jun 22, 2023Jun 26, 2023 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASEGRANT
Stock grant
6,989——6,989Jun 14, 2023Jun 16, 2023 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASE
400,000$30.00$12.00M3,570,872Mar 30, 2023Apr 3, 2023 ↗View →
ERAS
ERASCA, INC.
PURCHASE
307,692$6.50$2.00M10,813,246Dec 13, 2022Dec 21, 2022 ↗View →
ERAS
ERASCA, INC.
PURCHASE
307,692$6.50$2.00M10,813,246Dec 13, 2022Jul 22, 2021 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASEGRANT
Stock grant
23,867——23,867Jun 22, 2022Jun 24, 2022 ↗View →
PYXS
PYXIS ONCOLOGY, INC.
SALE
668,854——0Oct 13, 2021Oct 15, 2021 ↗View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
450,000$16.00$7.20M1,118,854Oct 13, 2021Oct 15, 2021 ↗View →
PYXS
PYXIS ONCOLOGY, INC.
PURCHASE
668,854——668,854Oct 13, 2021Oct 15, 2021 ↗View →
TYRA
TYRA BIOSCIENCES, INC.
SALE
757,432——0Sep 17, 2021Sep 21, 2021 ↗View →
TYRA
TYRA BIOSCIENCES, INC.
PURCHASE
312,500$16.00$5.00M1,069,932Sep 17, 2021Sep 21, 2021 ↗View →
TYRA
TYRA BIOSCIENCES, INC.
PURCHASE
757,432——757,432Sep 17, 2021Sep 21, 2021 ↗View →
IMRX
IMMUNEERING CORP
SALE
1,702,628——0Aug 3, 2021Aug 5, 2021 ↗View →
IMRX
IMMUNEERING CORP
PURCHASE
550,000$15.00$8.25M2,252,628Aug 3, 2021Aug 5, 2021 ↗View →
IMRX
IMMUNEERING CORP
PURCHASE
1,702,628——1,702,628Aug 3, 2021Aug 5, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
1,388,887——0Jul 20, 2021Jul 22, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
4,000,000——0Jul 20, 2021Jul 22, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
4,166,666——0Jul 20, 2021Jul 22, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
9,555,553——9,555,553Jul 20, 2021Jul 22, 2021 ↗View →
ERAS
ERASCA, INC.
PURCHASE
950,000$16.00$15.20M10,505,553Jul 20, 2021Jul 22, 2021 ↗View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
2,124,343——0Jun 28, 2021Jun 30, 2021 ↗View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
477,857——0Jun 28, 2021Jun 30, 2021 ↗View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
600,000$19.00$11.40M3,202,200Jun 28, 2021Jun 30, 2021 ↗View →
GLUE
MONTE ROSA THERAPEUTICS, INC.
PURCHASE
2,602,200——2,602,200Jun 28, 2021Jun 30, 2021 ↗View →
RAIN
RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC.
PURCHASE
2,326,657——2,326,657Apr 27, 2021Apr 29, 2021 ↗View →
RAIN
RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC.
PURCHASE
450,000$17.00$7.65M2,776,657Apr 27, 2021Apr 29, 2021 ↗View →
RAIN
RAIN ENHANCEMENT TECHNOLOGIES HOLDCO, INC.
SALE
2,512,561——0Apr 27, 2021Apr 29, 2021 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASE
2,270,872——0Apr 20, 2021Apr 22, 2021 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASE
2,270,872——2,270,872Apr 20, 2021Apr 22, 2021 ↗View →
BMEA
BIOMEA FUSION, INC.
PURCHASE
900,000$17.00$15.30M3,170,872Apr 20, 2021Apr 22, 2021 ↗View →
BMEA
BIOMEA FUSION, INC.
SALEGRANT
Stock grant
28,911——28,911Apr 15, 2021Apr 19, 2021 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASE
750,000$20.00$15.00M5,114,844Mar 30, 2021Apr 1, 2021 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
PURCHASE
4,364,844——4,364,844Mar 30, 2021Apr 1, 2021 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
SALE
1,404,953——0Mar 30, 2021Apr 1, 2021 ↗View →
DSGN
DESIGN THERAPEUTICS, INC.
SALE
2,959,891——0Mar 30, 2021Apr 1, 2021 ↗View →
BCAB
BIOATLA, INC.
PURCHASE
1,492,060——1,492,060Dec 18, 2020Dec 22, 2020 ↗View →
BCAB
BIOATLA, INC.
SALE
1,492,060——0Dec 18, 2020Dec 22, 2020 ↗View →
BCAB
BIOATLA, INC.
PURCHASE
800,000$18.00$14.40M2,292,060Dec 18, 2020Dec 22, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
425,000$19.00$8.07M3,270,544Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
2,122,367——0Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
SALE
723,177——0Nov 23, 2020Nov 23, 2020 ↗View →
OLMA
OLEMA PHARMACEUTICALS, INC.
PURCHASE
2,845,544——2,845,544Nov 23, 2020Nov 23, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
2,631,580——0Nov 3, 2020Nov 5, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
712,250——0Nov 3, 2020Nov 5, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
1,650,165——0Nov 3, 2020Nov 5, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
1,000,000——0Nov 3, 2020Nov 5, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
SALE
417,360——0Nov 3, 2020Nov 5, 2020 ↗View →
AVIR
ATEA PHARMACEUTICALS, INC.
PURCHASE
6,411,355——6,411,355Nov 3, 2020Nov 5, 2020 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
300,000$18.00$5.40M2,514,545Jun 16, 2020Jun 18, 2020 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
2,214,545——0Jun 16, 2020Jun 18, 2020 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
2,214,545——2,214,545Jun 16, 2020Jun 18, 2020 ↗View →
Other insiders · MLTX
Loading peer insiders…
About this filer
CIK 0001583977
ROLE
10% Owner
PRIMARY
MLTX
COMPANIES
19
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001583977DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback